Pacific Biosciences of California is back in focus after analysts cut their price target to $1.50 from $2, while a separate fair value estimate was trimmed to $2.43 from $2.50. This shift is tied to ...

PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.

PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results: Gross margin, operating expenses, net income ...

(RTTNews) - PacBio (PACB), a developer of highly accurate sequencing solutions, is slated to participate in several upcoming investor conferences this month, underscoring its visibility within the ...

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong third-quarter results, is expected to ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

PacBio reports that through its partnership with China-headquartered Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical ...